Angio-Ready™ Angiogenesis Assay System (ATCC® ACS-2001-2)

Organism: Homo sapiens, human  /  Cell Type: aortic endothelial and adipose mesenchymal stem cell  /  Tissue: aortic and adipose  /  Disease: normal

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue aortic and adipose
Cell Type aortic endothelial and adipose mesenchymal stem cell
Product Format frozen
Two 1 mL vials of cells
One 200 mL liquid medium kit
Morphology endothelial- and mesenchymal-like
Culture Properties adherent
Biosafety Level 2  [Cells containing SV40 viral DNA sequences]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease normal
Age 23 (TeloHAEC-GFP); N/A for hTERT-MSC
Gender both female
Ethnicity both Caucasian
Applications In vitro angiogenesis assay for drug screening, toxicity, pathway research, and gene function study
Shipping Information frozen, two 1 mL vials of cells (Angio-Ready™ Cells ACS-2007™) and one 200 mL liquid medium kit, Angio-Ready™ Angiogenesis Medium with VEGF Supplement (ACS-2008), shipped on dry ice
Storage Conditions cells at -130ºC; medium at -20ºC
Karyotype normal
Derivation Derived from aortic and adipose tissue; a proprietary mix of TeloHAEC-GFP (ATCC CRL-4054) and ASC52telo (ATCC SCRC-4000) hTERT-immortalized cells
Antigen Expression CD31 and CD90
Oncogene may contain viral sequences
Comments For details regarding Angio-Ready Angiogenesis Medium with VEGF Supplement see ATCC® ACS-2008
Complete Growth Medium Angio-Ready ™ Angiogenesis Medium with VEGF Supplement (ATCC® ACS-2008)
Seeding Density 7.5 x 104 per well of a 96-well plate (for other size plates refer to protocol)
Cryopreservation 90% FBS + 10% DMSO
Cells per Vial 7.5X106
Volume
Two 1 mL vials of cells
One 200 mL liquid medium kit
COI Human
Sterility Tests none detected
Viral Testing none detected
Functional Tests Pass – tubular formation assay
Population Doubling Time N/A
Name of Depositor ACS
Year of Origin N/A
Year of Deposit N/A
References

Hsu CW, et al. Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling. Oncotarget 7(7): 8172-8183, 2016. PubMed: 26882567

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
Restrictions

For commercial accounts, this cell line is only distributed under the terms of a fully signed and executed ATCC® Material Transfer Agreement and Addendum. If the commercial account is screening per completed Addendum, the recipient will be required to pay a Screening Fee (ATCC® ACS-2103F™).

Screening Use is defined as use of Biological Material in small molecule and biologic drug discovery, including initial target identification and validation, assay development, high throughput screening, hit identification, lead optimization, and selection of candidates for clinical development.

If the commercial account is not screening per the completed Addendum, the recipient will not be required to pay a Screening Fee.

References

Hsu CW, et al. Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling. Oncotarget 7(7): 8172-8183, 2016. PubMed: 26882567